Posts Tagged ‘candidate’
Dynavax Selects Clinical Candidate In Universal Flu Vaccine Program
Dynavax Technologies Corporation (NASDAQ: DVAX) announced that it has selected a clinical vaccine candidate for its novel Universal Flu program, completed key preclinical studies, and is reviewing clinical plans with the FDA in anticipation of initiating a Phase I study by mid-year…
Alkermes Announces Positive Results For Phase 1 Study Of New Drug Candidate For Treatment Of Opioid-Induced Constipation
Alkermes, Inc. (NASDAQ: ALKS) announced positive topline data from a phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC)…
NanoViricides, Inc. To Present Anti-Influenza Drug Candidate FluCide™ Studies At The Influenza Congress 2009
NanoViricides, Inc. (OTC BB: NNVC.OB) (the “Company”), announced that the Company’s CEO, Eugene Seymour, MD, MPH, has been invited to participate in a panel discussion at the Influenza Congress USA 2009, in Washington DC on November 19th (http://www.terrapinn.com/usaflu). The discussion will center on the “Evolving Role of Anti-Virals” in influenza treatment. Dr.
KemPharm, Inc. Expands Prodrug Pipeline With Candidate For Treatment Of Pain And Closes Series B Financing
KemPharm, Inc. announced the nomination of its second pipeline candidate, KP201, based on its proprietary ligand activated therapy (LAT) platform. KP201 is a new chemical entity (NCE) for the treatment of pain with the possibility of reduced abuse potential. KP201 joins lead candidate KP106, which is a novel prodrug candidate in development for ADHD. KemPharm also today announced the closing of a $3.
Inovio Biomedical, National Microbiology Laboratory, And University Of Pennsylvania To Evaluate Candidate DNA Vaccines Against “Swine” Influenza A
Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today it has established a new collaboration with the National Microbiology Laboratory of the Public Health Agency of Canada and the University of Pennsylvania to further evaluate Inovio DNA vaccine candidates against swine influenza A (H1N1) virus.
MAP Pharmaceuticals Phase 3 Trial Of Levadex? Migraine Product Candidate Meets All Four Primary Endpoints
MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced that the efficacy portion of its first Phase 3 clinical trial evaluating its novel LEVADEX? orally inhaled migraine therapy met all four primary endpoints. Additional endpoints showed that LEVADEX provided rapid and sustained pain relief for up to 48 hours after dosing.
MAP Pharmaceuticals Phase 3 Trial Of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints
MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced that the efficacy portion of its first Phase 3 clinical trial evaluating its novel LEVADEX(TM) orally inhaled migraine therapy met all four primary endpoints. Additional endpoints showed that LEVADEX provided rapid and sustained pain relief for up to 48 hours after dosing.
Rx Drug Compare
Translator
By N2H